{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:07:58Z","timestamp":1791472078282,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.11.004","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:20:17Z","timestamp":1763184017000},"page":"e201-e212.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Linvoseltamab in Patients With Relapsed\/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses"],"prefix":"10.1016","volume":"26","author":[{"given":"Hans C.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Zonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-3085","authenticated-orcid":false,"given":"Mansi R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-7344","authenticated-orcid":false,"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Maly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Namburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Pianko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Christine","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Lung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7571-1523","authenticated-orcid":false,"given":"Rebecca","family":"Silbermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christiane","family":"Vekemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Munder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"DeVeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito","family":"Roccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruti","family":"Chokshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-2909","authenticated-orcid":false,"given":"Megan","family":"Seraphin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5843-9057","authenticated-orcid":false,"given":"Kate","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Boyapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anasuya","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rodriguez Lorenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2897-9810","authenticated-orcid":false,"given":"Glenn S.","family":"Kroog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Bumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.11.004_bib0001","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.11.004_bib0002","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.3390\/cancers13205154","article-title":"Relapsed\/refractory multiple myeloma in 2020\/2021 and beyond","volume":"13","author":"Podar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.11.004_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00344-2","article-title":"The changing landscape of relapsed and\/or refractory multiple myeloma (MM): fundamentals and controversies","volume":"10","author":"Hern\u00e1ndez-Rivas","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.clml.2025.11.004_bib0004","doi-asserted-by":"crossref","DOI":"10.2196\/39068","article-title":"Characterizing the patient journey in multiple myeloma: qualitative review","volume":"8","author":"Lyall","year":"2022","journal-title":"JMIR Cancer"},{"key":"10.1016\/j.clml.2025.11.004_bib0005","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3390\/cancers15030567","article-title":"Non-conventional allogeneic anti-BCMA chimeric antigen receptor-based immune cell therapies for multiple myeloma treatment","volume":"15","author":"Du","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.11.004_bib0006","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.11.004_bib0007","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.11.004_bib0008","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.clml.2025.11.004_bib0009","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2025.11.004_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1397613","article-title":"Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma","volume":"14","author":"Medina-Olivares","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.11.004_bib0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-025-01262-4","article-title":"Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma","volume":"15","author":"Grischke","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.11.004_bib0012","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1182\/bloodadvances.2024013044","article-title":"CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations","volume":"8","author":"Perna","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.11.004_bib0013","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.11.004_bib0014","unstructured":"US Food and Drug Administration. CARTVYKTI\u24c7 (ciltacabtagene autoleucel). Highlights of prescribing information. https:\/\/www.fda.gov\/media\/156560\/download, 2025 (accessed 25 November 2025)."},{"key":"10.1016\/j.clml.2025.11.004_bib0015","unstructured":"US Food and Drug Administration. TECVAYLI (teclistamab-cqyv). Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf, 2022 (accessed 25 November 2025)."},{"key":"10.1016\/j.clml.2025.11.004_bib0016","unstructured":"US Food and Drug Administration. ELREXFIO\u2122 (elranatamab-bcmm). Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345s000lbl.pdf, 2023 (accessed 25 November 2025)."},{"key":"10.1016\/j.clml.2025.11.004_bib0017","unstructured":"US Food and Drug Administration. TALVEY\u2122 (talquetamab-tgvs). Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf, 2023 (accessed 25 November 2025)."},{"key":"10.1016\/j.clml.2025.11.004_bib0018","unstructured":"US Food and Drug Administration. LYNOZYFIC\u2122 (linvoseltamab-gcpt). Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761400s000lbl.pdf, 2025 (accessed 25 November 2025)."},{"key":"10.1016\/j.clml.2025.11.004_bib0019","unstructured":"European Medicines Agency. LYNOZYFIC. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynozyfic-epar-product-information_en.pdf, 2025 (accessed 25 November 2025)."},{"key":"10.1016\/j.clml.2025.11.004_bib0020","unstructured":"European Medicines Agency. ELREXFIO. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elrexfio-epar-product-information_en.pdf, 2024 (accessed 25 November 2025)."},{"key":"10.1016\/j.clml.2025.11.004_bib0021","unstructured":"European Medicines Agency. TALVEY. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talvey-epar-product-information_en.pdf, 2023 (accessed 25 November 2025)."},{"key":"10.1016\/j.clml.2025.11.004_bib0022","unstructured":"European Medicines Agency. TECVAYLI. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf, 2024 (accessed 25 November 2025)."},{"key":"10.1016\/j.clml.2025.11.004_bib0023","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.11.004_bib0024","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.11.004_bib0025","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.11.004_bib0026","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.11.004_bib0027","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.11.004_bib0028","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.11.004_bib0029","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.1016\/j.htct.2024.09.865","article-title":"Long-term follow-up from the phase 1\/2 MAJESTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma: subgroup analysis by lines of therapies","volume":"46","author":"Costa","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.clml.2025.11.004_bib0030","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1182\/blood-2024-208192","article-title":"MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma","volume":"144","author":"Prince","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.11.004_bib0031","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11523-022-00893-y","article-title":"Translational modeling predicts efficacious therapeutic dosing range of teclistamab for multiple myeloma","volume":"17","author":"Girgis","year":"2022","journal-title":"Target Oncol"},{"key":"10.1016\/j.clml.2025.11.004_bib0032","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-024-01129-0","article-title":"Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel","volume":"14","author":"Banerjee","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.11.004_bib0033","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.11.004_bib0034","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clml.2023.09.009","article-title":"Overall survival in patients with multiple myeloma in the U.S.: a systematic literature review of racial disparities","volume":"24","author":"Mikhael","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.11.004_bib0035","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.11.004_bib0036","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.11.004_bib0037","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.11.004_bib0038","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.11.004_bib0039","unstructured":"US Department of Health and Human Services, Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics, guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics, 2018 (accessed 25 November 2025)."},{"key":"10.1016\/j.clml.2025.11.004_bib0040","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.11.004_sbref0041","article-title":"National Cancer Institute. Surveillance, epidemiology, and end results program","year":"2025","journal-title":"Cancer Stat Facts: Myeloma. Vol"},{"key":"10.1016\/j.clml.2025.11.004_bib0042","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2025.11.004_bib0043","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-022-00665-x","article-title":"Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data","volume":"12","author":"Maignan","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.11.004_bib0044","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.clml.2025.11.004_bib0045","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2023-190102","article-title":"Elranatamab exposure-efficacy analysis in patients with relapsed or refractory multiple myeloma: insights from pooled Magnetismm studies","volume":"142","author":"Lon","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.11.004_bib0046","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.11.004_bib0047","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood-2023-189042","article-title":"The impact of treatment-free intervals on T-cell exhaustion and clonotypic diversity in myeloma patients treated with BCMA bispecific antibodies","volume":"142","author":"Eisele","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.11.004_bib0048","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2643-3230.BCD-24-0124","article-title":"T cell-redirecting bispecific antibodies in multiple myeloma: optimal dosing schedule and duration of treatment","volume":"5","author":"van de Donk","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2025.11.004_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.06.003","article-title":"Benign ethnic neutropenia","volume":"37","author":"Atallah-Yunes","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2025.11.004_bib0050","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1093\/hmg\/ddaa208","article-title":"The Duffy-null genotype and risk of infection","volume":"29","author":"Legge","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clml.2025.11.004_bib0051","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/bloodadvances.2022007679","article-title":"Absolute neutrophil count by Duffy status among healthy Black and African American adults","volume":"7","author":"Merz","year":"2023","journal-title":"Blood Advances"},{"key":"10.1016\/j.clml.2025.11.004_bib0052","series-title":"Presented at the 2025 ASCO Annual Meeting, Chicago, IL","article-title":"Linvoseltamab (LINVO)\u202f+\u202fbortezomib (BTZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): first results from the LINKER-MM2 trial","author":"Rodr\u00edguez-Otero","year":"2025"},{"key":"10.1016\/j.clml.2025.11.004_bib0053","series-title":"Presented at the 2025 ASCO Annual Meeting, Chicago, IL","article-title":"Linvoseltamab (LINVO)\u202f+\u202fcarfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial results from the LINKER-MM2 trial","author":"Manier","year":"2025"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:01:15Z","timestamp":1773900075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042831"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.11.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linvoseltamab in Patients With Relapsed\/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}